Processa Pharmaceuticals EBIT

Processa Pharmaceuticals (PCSA) currently reports a EBIT of $6.3M as of March 2026. That compares with $-13M in the prior-year period — up 149.7% year over year. That is below the Industrials sector average of $40B. Use the charts on this page to explore Processa Pharmaceuticals's EBIT history and peer comparisons.

Processa Pharmaceuticals's EBIT increased from $-13M to $6.3M — a 149.7% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Processa Pharmaceuticals's EBIT of $6.3M is lower than the Industrials sector average of $40B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Processa Pharmaceuticals reported $6.3M in EBIT as of March 2026. That compares with $-13M in the prior-year period — up 149.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $6.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is $40B. From there, open related valuation or income-statement pages for Processa Pharmaceuticals, and consider following PCSA for alerts when major investors trade the stock.